I-T raids premises of Cafe Coffee Day owner V G Siddhartha

Bengaluru, May 20: Karnataka Congress leaders held a protest against the state government against amending of APMC Act, at the premises of Vidhan Soudha here.

Few days ago, Karnataka Chief Minister BS Yediyurappa had said that the new amendment in the Agricultural Produce Marketing Committee (APMC) Act will substantially aid the farmers in getting remunerative price for their produce.

"Amendment will not dilute the powers of the work of the APMCs. All these marketing activities will be monitored by the Directorate of State APMC. This new amendment Act will benefit farmers in improving their income & suffering from losses due to market fluctuations," the Karnataka CM tweeted.

Yediyurappa further said that the amendment will indirectly help farmers in doubling their income by 2022.

"This amendment will indirectly help farmers in doubling their income by 2022. I want to clarify that we have not removed the APMC Act, we are only amending 2 sections of the APMC Act which enable farmers to sell their produce at the markets where they intend to," he tweeted.

Mysuru, Jan 21: South Indian actor Rashmika Mandanna, whose house was raided recently by IT sleuths, appeared for an inquiry along with her father Mr Madan Mandanna, here on Tuesday.

She arrived at the office of Principal Commissioner for IT, at Nazarbad, in the city. She was accompanied by nine persons, including auditors and accountants, who carried two backpacks and a kitbag.

Mr Madan mandanna said, "the IT officials have sought some documents and we are here to submit them."

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.